{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:16:50Z","timestamp":1790115410985,"version":"4.0.1"},"reference-count":52,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are complex autoimmune diseases with the potential to affect multiple organ systems and significantly impact quality of life. In the Middle East and North Africa (MENA), the burden of these conditions is amplified by a combination of genetic predisposition, environmental exposures, and socio-economic factors that shape both presentation and outcomes. High consanguinity rates, high ultraviolet exposure, infections, and lifestyle factors contribute to earlier onset and more aggressive disease, with lupus nephritis affecting up to 60% of patients. APS adds an additional layer of complexity through thrombotic events and pregnancy complications.\n                    <jats:bold>Purpose:<\/jats:bold>\n                    This review brings together current knowledge on the epidemiology, clinical patterns, and management challenges of SLE and APS across the region.\n                    <jats:bold>Results:<\/jats:bold>\n                    While individual country reports exist, the lack of large-scale registries limits our ability to fully define disease prevalence and outcomes. Delayed diagnosis, shortages of rheumatology specialists, and unequal access to advanced diagnostics and biologic therapies remain persistent barriers. In some low-resource or conflict-affected settings, even basic immunosuppressive medications are inconsistently available. The financial impact is substantial, driven by hospitalizations, medications, and loss of productivity, with many patients facing significant out-of-pocket costs. Recent advances, including biologics such as belimumab and anifrolumab, offer opportunities to improve outcomes but are not equitably accessible across the region.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Moving forward, investment in healthcare infrastructure, training, and culturally appropriate patient education will be essential. Establishing regional registries, expanding research into genetic and environmental risk factors, and developing locally relevant management strategies are critical next steps. By addressing these gaps through coordinated action between policymakers, healthcare providers, researchers, and patient communities, it is possible to reduce the disparities in care and improve survival, function, and quality of life for people living with SLE and APS in the MENA region.\n                  <\/jats:p>","DOI":"10.1177\/09612033251408525","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T04:31:11Z","timestamp":1766205071000},"page":"208-217","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Epidemiological perspectives on SLE and APS in MENA: Burden, barriers, and a path toward improved outcomes"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0353-895X","authenticated-orcid":false,"given":"Rajaie","family":"Namas","sequence":"first","affiliation":[{"name":"Cleveland Clinic Abu Dhabi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0058-1581","authenticated-orcid":false,"given":"Sarah","family":"Al Qassimi","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Abu Dhabi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6169-7284","authenticated-orcid":false,"given":"Ahlam","family":"Almarzooqi","sequence":"additional","affiliation":[{"name":"Al Qassimi Hospital"},{"name":", Emirates Health Services"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex260"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00668-1"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1477708"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320950477"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead618"},{"issue":"5","key":"e_1_3_3_7_2","first-page":"471","article-title":"Epidemiology of systemic lupud erythematosus in central Saudi Arabia","volume":"42","author":"Al-Arfaj AS","year":"2021","unstructured":"Al-Arfaj AS, Suliman RA, Al-Dalaan AN, Al-Saleh SS, Bahabri SA, Mousa MM, Sekeit MA, et al. Epidemiology of systemic lupud erythematosus in central Saudi Arabia. Saudi Med J. 2021; 42(5): 471\u2013475.","journal-title":"Saudi Med J"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/02724936.1997.11747879"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211014253"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1435306"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316678677"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2318996"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.5606\/ArchRheumatol.2018.6832"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2022.07.003"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307084297"},{"issue":"1","key":"e_1_3_3_16_2","first-page":"90","article-title":"Assessment of lupus nephritis in a multicenter retrospective Egyptian cohort: initial characteristics, influence of age and gender, outcome, and potential association with disease damage","volume":"33","author":"Medhat BM","year":"2022","unstructured":"Medhat BM, Elmaghraby A, Farag Y, et al. Assessment of lupus nephritis in a multicenter retrospective Egyptian cohort: initial characteristics, influence of age and gender, outcome, and potential association with disease damage. Saudi J Kidney Dis Transpl 2022; 33(1): 90\u2013105.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-021-00222-3"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221122982"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319889663"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101180"},{"issue":"1","key":"e_1_3_3_21_2","first-page":"i67","article-title":"The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus","volume":"56","author":"Lewis MJ","year":"2017","unstructured":"Lewis MJ, Jawad AS. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology 2017; 56(Suppl_1): i67\u2013i77.","journal-title":"Rheumatology"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0102-3"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.02.002"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037821"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13082211"},{"issue":"4","key":"e_1_3_3_26_2","first-page":"e57842","article-title":"Cardiovascular morbidity in systemic lupus erythematosus: a single-center retrospective study","volume":"16","author":"Alammari Y","year":"2024","unstructured":"Alammari Y, Albednah FA, Alharbi KA, et al. Cardiovascular morbidity in systemic lupus erythematosus: a single-center retrospective study. Cureus 2024; 16(4): e57842.","journal-title":"Cureus"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S448186"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000078"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06055-9"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241292203"},{"issue":"1","key":"e_1_3_3_31_2","first-page":"e80","article-title":"Clinical and laboratory manifestations of Yemeni patients with systemic lupus erythematosus","volume":"14","author":"Al-Shamahy HA","year":"2014","unstructured":"Al-Shamahy HA, Dhaifallah NH, Al-Ezzy YM. Clinical and laboratory manifestations of Yemeni patients with systemic lupus erythematosus. Sultan Qaboos Univ Med J 2014; 14(1): e80\u2013e87.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.011123.fst"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25528"},{"issue":"1","key":"e_1_3_3_35_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","author":"Kidney Disease Improving Global Outcomes KDIGO Lupus Nephritis Work Group","year":"2024","unstructured":"Kidney Disease Improving Global Outcomes KDIGO Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int 2024; 105(1S): S1\u2013S69.","journal-title":"Kidney Int"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213512"},{"issue":"12","key":"e_1_3_3_37_2","first-page":"1210","article-title":"Long-term safety and efficacy of glucocorticoids in systemic lupus erythematosus: a systematic literature review","volume":"13","author":"van Vollenhoven RF","year":"2014","unstructured":"van Vollenhoven RF, Petri MA, Cervera R, et al. Long-term safety and efficacy of glucocorticoids in systemic lupus erythematosus: a systematic literature review. Autoimmun Rev 2014; 13(12): 1210\u20131223.","journal-title":"Autoimmun Rev"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.027"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24901"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2023.59.2.3521876"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04795-9"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-018-0232-2"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.7748\/ns.26.39.49.s53"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.4103\/ara.ara_15_23"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2013.05.009"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2354457"},{"issue":"7","key":"e_1_3_3_48_2","first-page":"15","article-title":"Deciphering mechanisms, prevention strategies, management plans, medications, and research techniques for strokes in systemic lupus erythematosus","volume":"11","author":"Al-Ewaidat OA","year":"2024","unstructured":"Al-Ewaidat OA, Naffaa MM. Deciphering mechanisms, prevention strategies, management plans, medications, and research techniques for strokes in systemic lupus erythematosus. Medicine 2024; 11(7): 15.","journal-title":"Medicine"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202351"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead303"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.3390\/antib13010021"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.06.24308533"},{"key":"e_1_3_3_53_2","volume-title":"Presented at: ACR convergence 2023","author":"Al-Saleh J","year":"2023","unstructured":"Al-Saleh J, Elbadawi F, Namas R, et al. Demographic and clinical characteristics of patients with LN: a multicenter study from the gulf region Presented at: ACR convergence 2023, 2023 Poster Hall. Funded by GSK."}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251408525","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033251408525","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251408525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:29:33Z","timestamp":1777678173000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033251408525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/09612033251408525"],"URL":"https:\/\/doi.org\/10.1177\/09612033251408525","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}